BMS and Hengrui Form $15 Billion Drug Development Alliance
SHANGHAI, China and PRINCETON, N.J., May 12, 2026 Hengrui Pharma and Bristol Myers Squibb (BMS) have announced a landmark...
Bristol Myers Squibb
Advertisement
Bristol Myers Squibb Secures EU Approval for Sotyktu in Psoriatic Arthritis
PRINCETON, N.J., May 11, 2026 Bristol Myers Squibb announced that the European Commission has approved Sotyktu (deucravacitinib) for the...
Atrium Therapeutics Earns $15M Milestone from Bristol Myers Squibb
San Diego, California, USA – April 23, 2026 Atrium Therapeutics announced it has achieved a $15 million development milestone...
Bristol Myers Camzyos Shows Strong Results in HCM Trial
PRINCETON, N.J., USA, March 29, 2026 Bristol Myers Squibb has announced positive Phase 3 results from the SCOUT-HCM trial...
Bristol Myers Squibb Reports New Camzyos Data at ACC
PRINCETON, NEW JERSEY, March 23, 2026 Bristol Myers Squibb has unveiled new clinical and real-world data for Camzyos (mavacamten)...
Advertisements
Iza-bren Meets Dual Endpoints in Phase III TNBC
REDMOND, Wash. & PRINCETON, N.J., February 26, 2026 SystImmune, Inc. and Bristol Myers Squibb announced positive interim topline results...
BMS to Spotlight Pipeline at TD Cowen Health Meet
NEW YORK, Feb. 24, 2026 — Bristol Myers Squibb announced its participation in the upcoming TD Cowen 46th Annual...
Janux and BMS Partner on Tumor-Activated Cancer Therapy
SAN DIEGO, January 22, 2026 — Janux Therapeutics announced a collaboration and exclusive worldwide license agreement with Bristol Myers...
Bristol Myers Squibb Unveils New Long-Term and Real-World Data for Camzyos at AHA 2025
Princeton, N.J., November 4, 2025 – Bristol Myers Squibb (NYSE: BMY) announced a major scientific milestone with the presentation...
Bristol Myers Squibb’s Iberdomide Shows Strong Phase 3 Results in Multiple Myeloma
Princeton, N.J., September 22, 2025 – Bristol Myers Squibb (BMS) announced that its investigational cereblon E3 ligase modulator (CELMoD™)...
Advertisement
